Chemomab Therapeutics Ltd. (CMMB)
- Previous Close
0.6700 - Open
0.6800 - Bid --
- Ask --
- Day's Range
0.6500 - 0.6800 - 52 Week Range
0.4200 - 1.8900 - Volume
3,376 - Avg. Volume
224,501 - Market Cap (intraday)
9.517M - Beta (5Y Monthly) -0.04
- PE Ratio (TTM)
-- - EPS (TTM)
-2.0600 - Earnings Date May 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
www.chemomab.comRecent News: CMMB
Performance Overview: CMMB
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CMMB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CMMB
Valuation Measures
Market Cap
9.52M
Enterprise Value
-9.87M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.56
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.39
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-48.80%
Return on Equity (ttm)
-91.02%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-24.22M
Diluted EPS (ttm)
-2.0600
Balance Sheet and Cash Flow
Total Cash (mrq)
19.78M
Total Debt/Equity (mrq)
2.31%
Levered Free Cash Flow (ttm)
-15.49M